JPS5229888B2
(fr)
|
1972-02-01 |
1977-08-04 |
|
|
US4769320A
(en)
|
1982-07-27 |
1988-09-06 |
New England Medical Center Hospitals, Inc. |
Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
|
CA1209907A
(fr)
*
|
1982-04-12 |
1986-08-19 |
Richard M. Bartholomew |
Methode de purification par affinite ayant recours a des anticorps monoclonaux
|
JPS58201994A
(ja)
|
1982-05-21 |
1983-11-25 |
Hideaki Hagiwara |
抗原特異的ヒト免疫グロブリンの生産方法
|
US4689299A
(en)
*
|
1982-09-30 |
1987-08-25 |
University Of Rochester |
Human monoclonal antibodies against bacterial toxins
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6088703A
(ja)
|
1983-10-18 |
1985-05-18 |
新日本製鐵株式会社 |
耐重荷重性舗装体
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
JPH06104071B2
(ja)
|
1986-08-24 |
1994-12-21 |
財団法人化学及血清療法研究所 |
第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
|
US4801687A
(en)
*
|
1986-10-27 |
1989-01-31 |
Bioprobe International, Inc. |
Monoclonal antibody purification process using protein A
|
JPS63149900A
(ja)
|
1986-12-15 |
1988-06-22 |
Toshiba Corp |
半導体メモリ
|
US4851341A
(en)
|
1986-12-19 |
1989-07-25 |
Immunex Corporation |
Immunoaffinity purification system
|
JPH01144991A
(ja)
|
1987-12-02 |
1989-06-07 |
Kagaku Oyobi Ketsusei Riyouhou Kenkyusho |
血液凝固第8因子の精製方法
|
US5670373A
(en)
*
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5322678A
(en)
*
|
1988-02-17 |
1994-06-21 |
Neorx Corporation |
Alteration of pharmacokinetics of proteins by charge modification
|
RO105652B1
(ro)
|
1988-09-28 |
1992-11-30 |
Lilly Co Eli |
Procedeu de reducere a heterogenitatii anticorpilor monoclonali
|
US5126250A
(en)
*
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
CA2006684C
(fr)
|
1988-12-30 |
1996-12-17 |
Charles T. Esmon |
Anticorps monoclonaux contre la proteine c
|
US5202253A
(en)
|
1988-12-30 |
1993-04-13 |
Oklahoma Medical Research Foundation |
Monoclonal antibody specific for protein C and antibody purification method
|
JPH0636741B2
(ja)
|
1989-11-08 |
1994-05-18 |
帝人株式会社 |
ヒト・プロテインcの分離方法
|
CA2075927A1
(fr)
|
1990-02-16 |
1991-08-17 |
Victor A. Raso |
Reactifs hybrides ayant un pouvoir de liberation selective de molecules dans les cellules
|
US5130129A
(en)
|
1990-03-06 |
1992-07-14 |
The Regents Of The University Of California |
Method for enhancing antibody transport through capillary barriers
|
ATE185601T1
(de)
|
1990-07-10 |
1999-10-15 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
GB9022547D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Purified immunoglobulin
|
WO1992019759A1
(fr)
*
|
1991-04-25 |
1992-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
|
US5468634A
(en)
*
|
1991-06-24 |
1995-11-21 |
The University Of North Carolina At Chapel Hill |
Axl oncogene
|
JP3087857B2
(ja)
|
1991-07-04 |
2000-09-11 |
東洋紡績株式会社 |
交編編地の染色処理方法
|
DE69229477T2
(de)
|
1991-09-23 |
1999-12-09 |
Cambridge Antibody Tech |
Methoden zur Herstellung humanisierter Antikörper
|
US5885793A
(en)
|
1991-12-02 |
1999-03-23 |
Medical Research Council |
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
|
CA2124967C
(fr)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Animaux transgeniques non humains capables de produire des anticorps heterologues
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
EP0656941B1
(fr)
|
1992-03-24 |
2005-06-01 |
Cambridge Antibody Technology Limited |
Procedes de production d'elements de paires de liaison specifiques
|
EP0640094A1
(fr)
|
1992-04-24 |
1995-03-01 |
The Board Of Regents, The University Of Texas System |
Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
BR9204244A
(pt)
|
1992-10-26 |
1994-05-03 |
Cofap |
Ferro fundido cinzento
|
WO1994012215A1
(fr)
|
1992-12-01 |
1994-06-09 |
Protein Design Labs, Inc. |
Anticorps humanises reagissant avec l-selectine
|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
ES2201076T3
(es)
|
1993-03-19 |
2004-03-16 |
The Johns Hopkins University School Of Medicine |
Factor-8 de diferenciacion del crecimiento.
|
EP0710288B1
(fr)
*
|
1993-06-10 |
2006-04-05 |
Genetic Therapy, Inc. |
Vecteurs adenoviraux pour le traitement de l'hemophilie
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
FR2707189B1
(fr)
|
1993-07-09 |
1995-10-13 |
Gradient Ass |
Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
|
GB9314271D0
(en)
|
1993-07-09 |
1993-08-18 |
Inst Of Cancer The Research |
Cell growth factor receptors
|
IL107742A0
(en)
|
1993-11-24 |
1994-02-27 |
Yeda Res & Dev |
Chemically-modified binding proteins
|
CA2177367A1
(fr)
|
1993-12-03 |
1995-06-08 |
Andrew David Griffiths |
Proteines et peptides de liaison recombines
|
EP0732404A4
(fr)
|
1993-12-03 |
1997-07-30 |
Asahi Chemical Ind |
Nouveau vecteur de detection d'expression
|
JPH07177572A
(ja)
|
1993-12-20 |
1995-07-14 |
Matsushita Electric Ind Co Ltd |
コードレス電話の留守番方法
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
US5945311A
(en)
*
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
DE4419399C1
(de)
|
1994-06-03 |
1995-03-09 |
Gsf Forschungszentrum Umwelt |
Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
|
US8017121B2
(en)
*
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
HU220347B
(hu)
|
1994-07-11 |
2001-12-28 |
Board Of Regents The University Of Texas System |
Készítmény az érrendszer specifikus koagulálásához
|
US6048972A
(en)
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
TW416960B
(en)
|
1994-07-13 |
2001-01-01 |
Chugai Pharmaceutical Co Ltd |
Reshaped human antibody to human interleukin-8
|
KR100261941B1
(ko)
|
1994-07-13 |
2000-07-15 |
나가야마 오사무 |
사람의 인터루킨-8에 대한 재구성 사람항체
|
JP3865418B2
(ja)
|
1994-07-13 |
2007-01-10 |
中外製薬株式会社 |
ヒトインターロイキン−8に対する再構成ヒト抗体
|
CN1156460A
(zh)
|
1994-07-13 |
1997-08-06 |
中外制药株式会社 |
抗人白细胞介素-8的重构人抗体
|
US6309636B1
(en)
|
1995-09-14 |
2001-10-30 |
Cancer Research Institute Of Contra Costa |
Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
|
AU700819B2
(en)
|
1994-10-07 |
1999-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
|
CN101829325A
(zh)
|
1994-10-21 |
2010-09-15 |
岸本忠三 |
Il-6受体的抗体在制备药物组合物中的用途
|
US5876950A
(en)
|
1995-01-26 |
1999-03-02 |
Bristol-Myers Squibb Company |
Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
CA2761116A1
(fr)
|
1995-04-27 |
1996-10-31 |
Amgen Fremont Inc. |
Anticorps humains derives d'une xenosouris immunisee
|
CA2219486A1
(fr)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Anticorps humains derives de xeno-souris immunisees
|
US5830478A
(en)
|
1995-06-07 |
1998-11-03 |
Boston Biomedical Research Institute |
Method for delivering functional domains of diphtheria toxin to a cellular target
|
CN1241944C
(zh)
|
1995-09-11 |
2006-02-15 |
协和发酵工业株式会社 |
抗人白介素-5受体α链的抗体
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
EP0938499A1
(fr)
|
1996-07-19 |
1999-09-01 |
Amgen Inc. |
Analogues de proteines cationiques
|
EP0918872B1
(fr)
|
1996-08-02 |
2008-02-20 |
Bristol-Myers Squibb Company |
Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
IL129164A
(en)
|
1996-09-26 |
2007-05-15 |
Chugai Pharmaceutical Co Ltd |
An antibody against peptides associated with human parathyroid hormone
|
US6025158A
(en)
|
1997-02-21 |
2000-02-15 |
Genentech, Inc. |
Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
ATE407696T1
(de)
|
1997-03-21 |
2008-09-15 |
Chugai Pharmaceutical Co Ltd |
Vorbeugende- oder heilmittel zur behandlung von multipler sklerose, mit antagonistischen anti-il6-rezeptor antikörpern als wirkstoff
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
FR2761994B1
(fr)
|
1997-04-11 |
1999-06-18 |
Centre Nat Rech Scient |
Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
|
JP4086908B2
(ja)
|
1997-04-17 |
2008-05-14 |
アムジエン・インコーポレーテツド |
安定かつ活性なヒトOBタンパク質と抗体Fc鎖とのコンジュゲートを含む組成物および方法
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック,インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
US5980893A
(en)
|
1997-07-17 |
1999-11-09 |
Beth Israel Deaconess Medical Center, Inc. |
Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
|
US20020187150A1
(en)
*
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
KR20080027967A
(ko)
|
1997-08-15 |
2008-03-28 |
츄가이 세이야꾸 가부시키가이샤 |
항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
|
RU2221809C2
(ru)
*
|
1997-10-03 |
2004-01-20 |
Тугаи Сейяку Кабусики Кайся |
Способ получения природного гуманизированного антитела
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
DK1074268T3
(da)
|
1998-03-17 |
2008-04-28 |
Chugai Pharmaceutical Co Ltd |
IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
ES2340112T3
(es)
|
1998-04-20 |
2010-05-28 |
Glycart Biotechnology Ag |
Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
CA2341029A1
(fr)
*
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Production de molecules modifiees avec demi-vie serique prolongee
|
US6475718B2
(en)
|
1998-09-08 |
2002-11-05 |
Schering Aktiengesellschaft |
Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
|
KR100483494B1
(ko)
*
|
1998-12-01 |
2005-04-15 |
프로테인 디자인 랩스 인코포레이티드 |
감마 인터페론에 대한 인간화 항체
|
JP2002534959A
(ja)
|
1998-12-08 |
2002-10-22 |
バイオベーション リミテッド |
免疫原性タンパク質の改変方法
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2000042072A2
(fr)
|
1999-01-15 |
2000-07-20 |
Genentech, Inc. |
Variants polypeptidiques ayant une fonction effectrice alteree
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
AU2006225302B2
(en)
|
1999-03-25 |
2010-08-12 |
AbbVie Deutschland GmbH & Co. KG |
Human antibodies that bind human IL-12 and methods for producing
|
EP1176195B1
(fr)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
|
EP2135953B1
(fr)
|
1999-06-02 |
2014-04-23 |
Chugai Seiyaku Kabushiki Kaisha |
Protéine réceptrice d'hémopoïétine, Nr. 10
|
US6331642B1
(en)
|
1999-07-12 |
2001-12-18 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
SK782002A3
(en)
*
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US20040058393A1
(en)
|
2000-04-17 |
2004-03-25 |
Naoshi Fukishima |
Agonist antibodies
|
AU6627201A
(en)
|
2000-05-03 |
2001-11-12 |
Mbt Munich Biotechnology Gmbh |
Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
|
KR20120053525A
(ko)
*
|
2000-06-16 |
2012-05-25 |
캠브리지 안티바디 테크놀로지 리미티드 |
면역특이적으로 BLyS에 결합하는 항체
|
AU2011244851A1
(en)
|
2000-07-27 |
2011-11-24 |
The John Hopkins University School Of Medicine |
Promyostatin peptides and methods of using same
|
CA2421447C
(fr)
|
2000-09-08 |
2012-05-08 |
Universitat Zurich |
Groupes de proteines a domaines de repetition comprenant des modules de repetition
|
PL218428B1
(pl)
|
2000-10-06 |
2014-12-31 |
Kyowa Hakko Kogyo Kk |
Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
|
PT1325033E
(pt)
|
2000-10-10 |
2010-04-15 |
Genentech Inc |
Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
|
CA2418835A1
(fr)
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison
|
JP4776145B2
(ja)
|
2000-10-25 |
2011-09-21 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する乾癬の予防又は治療剤
|
JP4889187B2
(ja)
*
|
2000-10-27 |
2012-03-07 |
中外製薬株式会社 |
Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤
|
EP2341060B1
(fr)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules a demi-vies longues, compositions et utilisations de celles-ci
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
CA2442801A1
(fr)
|
2001-04-02 |
2002-10-10 |
Idec Pharmaceutical Corporation |
Anticorps recombinants co-exprimes avec gntiii
|
WO2002083854A2
(fr)
*
|
2001-04-13 |
2002-10-24 |
Biogen, Inc. |
Anticorps anti-vla-1
|
US7667004B2
(en)
*
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
EP2208784B1
(fr)
*
|
2001-06-22 |
2013-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de prolifération de cellules contenant un anticorps anti-glypican 3
|
ATE477280T1
(de)
|
2001-06-28 |
2010-08-15 |
Domantis Ltd |
Doppelspezifischer ligand und dessen verwendung
|
US20040161741A1
(en)
|
2001-06-30 |
2004-08-19 |
Elazar Rabani |
Novel compositions and processes for analyte detection, quantification and amplification
|
BRPI0211953B8
(pt)
|
2001-08-17 |
2021-05-25 |
Genentech Inc |
anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US20030190705A1
(en)
|
2001-10-29 |
2003-10-09 |
Sunol Molecular Corporation |
Method of humanizing immune system molecules
|
EP1562968B1
(fr)
|
2001-11-14 |
2013-08-21 |
Janssen Biotech, Inc. |
Anticorps anti-il-6, compositions, methodes et utilisations associees
|
CA2467633C
(fr)
|
2001-12-03 |
2012-03-27 |
Abgenix, Inc. |
Categorisation d'anticorps reposant sur des caracteristiques de liaison
|
EP3960855A1
(fr)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de stabilisation de protéines
|
CA2473733C
(fr)
*
|
2002-01-18 |
2014-09-09 |
Zymogenetics, Inc. |
Recepteurs multimeres des cytokines contenant zcytor17
|
JP4795641B2
(ja)
|
2002-01-18 |
2011-10-19 |
ザイモジェネティクス, インコーポレイテッド |
新規サイトカインzcytor17リガンド
|
AU2003216250A1
(en)
|
2002-02-11 |
2003-09-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
US20050130224A1
(en)
*
|
2002-05-31 |
2005-06-16 |
Celestar Lexico- Sciences, Inc. |
Interaction predicting device
|
WO2003102580A1
(fr)
|
2002-05-31 |
2003-12-11 |
Biacore Ab |
Technique de couplage d'agents de liaison a la surface d'un substrat
|
EP2107116A3
(fr)
|
2002-06-12 |
2009-12-09 |
Genencor International, Inc. |
Procédés d'amélioration des caractéristiques de liaison d'une molécule
|
WO2003105757A2
(fr)
*
|
2002-06-12 |
2003-12-24 |
Genencor International, Inc. |
Methodes et compositions de liaison dependant du milieu d'un agent cible a une cible
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
EP1382969A1
(fr)
|
2002-07-17 |
2004-01-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Diagnostic et traitement de l'invasion des cellules cancéreuses
|
EP1578928B1
(fr)
|
2002-09-16 |
2010-03-17 |
The Johns Hopkins University |
Activation de la myostatine dont la mediation est assuree par metalloprotease, et procedes relatifs a la modulation de l'activite de la myostatine
|
BRPI0314814C1
(pt)
|
2002-09-27 |
2021-07-27 |
Xencor Inc |
anticorpo compreendendo uma variante de fc
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
CA2502904C
(fr)
|
2002-10-15 |
2013-05-28 |
Protein Design Labs, Inc. |
Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
|
AU2003285874A1
(en)
*
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
NZ541050A
(en)
|
2002-12-16 |
2010-06-25 |
Genmab As |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
JP2006523090A
(ja)
|
2002-12-27 |
2006-10-12 |
ドマンティス リミテッド |
リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
|
WO2005020936A2
(fr)
|
2003-02-28 |
2005-03-10 |
Antigenics Inc. |
Utilisation de lectines en vue de promouvoir l'oligomerisation des glycoproteines et des molecules antigeniques
|
US20040223970A1
(en)
*
|
2003-02-28 |
2004-11-11 |
Daniel Afar |
Antibodies against SLC15A2 and uses thereof
|
WO2004076485A1
(fr)
|
2003-02-28 |
2004-09-10 |
Lonza Biologics Plc. |
Purification d'anticorps par chromatographie d'affinite sur proteine a et chromatographie par echange d'ions
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP2006521387A
(ja)
|
2003-03-04 |
2006-09-21 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
|
ATE475673T1
(de)
|
2003-03-24 |
2010-08-15 |
Zymogenetics Inc |
Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
AU2004245025A1
(en)
|
2003-06-02 |
2004-12-16 |
Wyeth |
Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
|
JP2005004970A
(ja)
|
2003-06-09 |
2005-01-06 |
Hitachi Cable Ltd |
複合ケーブルおよびこれを用いた先行配線システム
|
WO2004113387A2
(fr)
|
2003-06-24 |
2004-12-29 |
Merck Patent Gmbh |
Molecules de recepteur du facteur de necrose tumorale a immunogenicite reduite
|
US7011924B2
(en)
*
|
2003-07-30 |
2006-03-14 |
Hynix Semiconductor Inc. |
Photoresist polymers and photoresist compositions comprising the same
|
WO2005023193A2
(fr)
|
2003-09-04 |
2005-03-17 |
Interleukin Genetics, Inc. |
Methodes permettant de traiter l'endometriose
|
WO2005027966A2
(fr)
*
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Anticorps aux fonctions d'effecteur modifiees
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2003271186A1
(en)
*
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
JP2007531707A
(ja)
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ, インコーポレイテッド |
IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
|
AR046290A1
(es)
|
2003-10-17 |
2005-11-30 |
Chugai Pharmaceutical Co Ltd |
Agente terapeutico para el mesotelioma
|
WO2005040229A2
(fr)
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
|
ME01198B
(fr)
*
|
2003-11-05 |
2013-03-20 |
Ares Trading Sa |
Procede de purification de la proteine de liaison il-18
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
WO2005047327A2
(fr)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
|
EP1701979A2
(fr)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
|
WO2005056759A2
(fr)
|
2003-12-04 |
2005-06-23 |
Xencor, Inc. |
Procedes pour produire des proteines variantes presentant une plus grande concentration en chaine hote et compositions de celles-ci
|
CN102838675B
(zh)
*
|
2003-12-10 |
2014-07-30 |
梅达雷克斯有限责任公司 |
Ip-10抗体及其用途
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
WO2005077981A2
(fr)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Polypeptides fc a nouveaux sites de liaison de ligands fc
|
UA93855C2
(ru)
|
2003-12-31 |
2011-03-25 |
Шеринг-Плау Лтд. |
Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
|
BRPI0506771A
(pt)
|
2004-01-12 |
2007-05-22 |
Applied Molecular Evolution |
anticorpo, e, composição farmacêutica
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US20070116710A1
(en)
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
ES2341461T5
(es)
|
2004-02-11 |
2014-10-29 |
Warner-Lambert Company Llc |
Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
|
KR20060133049A
(ko)
|
2004-03-23 |
2006-12-22 |
일라이 릴리 앤드 캄파니 |
항-마이오스타틴 항체
|
EP1728801A4
(fr)
|
2004-03-24 |
2009-10-21 |
Chugai Pharmaceutical Co Ltd |
Sous-type d' anticorps humanise contre un recepteur de l'interleukine-6
|
KR20070035482A
(ko)
|
2004-03-24 |
2007-03-30 |
추가이 세이야쿠 가부시키가이샤 |
인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
WO2005123780A2
(fr)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
|
KR20070038453A
(ko)
|
2004-04-16 |
2007-04-10 |
마크로제닉스, 인크. |
FcγRIIB-특이적 항체 및 그의 사용 방법
|
CA2568952C
(fr)
*
|
2004-06-18 |
2019-05-21 |
Ambrx, Inc. |
Nouveaux polypeptides de liaison a l'antigene et leurs utilisations
|
EP1773391A4
(fr)
|
2004-06-25 |
2009-01-21 |
Medimmune Inc |
Augmentation de la production d'anticorps de recombinaison dans des cellules de mamiferes par mutagenese sur le site
|
DE102004032634A1
(de)
|
2004-07-06 |
2006-02-16 |
Sms Demag Ag |
Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
|
BRPI0513155B1
(pt)
|
2004-07-06 |
2021-07-20 |
Bioren, Inc. |
Método de distinguir um ou mais resíduos de aminoácido funcionais dos resíduos de aminoácido não-funcionais em uma região definida dentro de um polipeptídeo, método de gerar uma biblioteca de análogos de polipeptídeo e método de identificar um subconjunto de análogos de polipeptídeo tendo uma propriedade desejada
|
WO2006085967A2
(fr)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
Anticorps monoclonaux optimises anti-cd20 a variants fc
|
BRPI0510674A
(pt)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
variantes fc otimizadas
|
MX2007000644A
(es)
*
|
2004-07-20 |
2007-03-28 |
Symphogen As |
Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
|
EP2213683B1
(fr)
|
2004-08-04 |
2013-06-05 |
Mentrik Biotech, LLC |
Régions Fc variantes
|
CA2577329A1
(fr)
|
2004-08-16 |
2006-03-02 |
Medimmune, Inc. |
Variants fc de liaison a un recepteur eph presentant une activite cytotoxique cellulaire dependant des anticorps
|
AU2005285347A1
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2006047350A2
(fr)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
Variants d'immunoglobuline igg a fonction effectrice optimisee
|
JP2008520552A
(ja)
|
2004-10-22 |
2008-06-19 |
メディミューン,インコーポレーテッド |
Hmgb1に対する高親和性の抗体およびその使用法
|
AU2005299716B2
(en)
*
|
2004-10-22 |
2012-09-06 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
EP1812068A4
(fr)
|
2004-10-29 |
2010-06-09 |
Medimmune Inc |
Méthodes de prévention et de traitement des infections à rsv et des états pathologiques associés
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CN101098890B
(zh)
|
2004-11-12 |
2012-07-18 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US8329186B2
(en)
|
2004-12-20 |
2012-12-11 |
Isu Abxis Co., Ltd |
Treatment of inflammation using BST2 inhibitor
|
JPWO2006067847A1
(ja)
|
2004-12-22 |
2008-06-12 |
中外製薬株式会社 |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
WO2006066598A2
(fr)
|
2004-12-23 |
2006-06-29 |
Novo Nordisk A/S |
Ligands affinitaires se liant a des anticorps
|
US20090087478A1
(en)
|
2004-12-27 |
2009-04-02 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
|
HUE026107T2
(en)
|
2004-12-28 |
2016-05-30 |
Innate Pharma |
Monoclonal antibody to NKG2A
|
EP1858925A2
(fr)
|
2005-01-12 |
2007-11-28 |
Xencor, Inc. |
Anticorps et proteines de fusion fc a immunogenicite modifiee
|
GB0502358D0
(en)
|
2005-02-04 |
2005-03-16 |
Novartis Ag |
Organic compounds
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
WO2006088855A1
(fr)
*
|
2005-02-14 |
2006-08-24 |
Zymogenetics, Inc. |
Méthodes de traitement d’affections de la peau en employant un antagoniste de il-31ra
|
CA2602035C
(fr)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Rearrangement de l'infrastructure d'anticorps
|
ES2592271T3
(es)
|
2005-03-31 |
2016-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
|
CA2602663A1
(fr)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Variants fc presentant des proprietes optimisees
|
EP1870458B1
(fr)
|
2005-03-31 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
ISOMERES STRUCTURELS sc(Fv)2
|
EP1876236B9
(fr)
|
2005-04-08 |
2015-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps de substitution de la fonction du facteur viii de coagulation sanguine
|
ES2545769T3
(es)
*
|
2005-04-18 |
2015-09-15 |
Amgen Research (Munich) Gmbh |
Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano
|
EP1874820A4
(fr)
|
2005-04-20 |
2010-09-22 |
Amgen Fremont Inc |
Anticorps monoclonaux entièrement humains à affinité élevée d'interleukine-8 et épitopes destinés à ces anticorps
|
DOP2006000093A
(es)
|
2005-04-25 |
2007-01-31 |
Pfizer |
Anticuerpos contra miostatina
|
WO2006116260A2
(fr)
|
2005-04-26 |
2006-11-02 |
Medimmune, Inc. |
Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
WO2007143231A2
(fr)
|
2006-01-10 |
2007-12-13 |
Zymogenetics, Inc. |
Procédés de traitement de la douleur et de l'inflammation dans les tissus neuronaux au moyen d'antagonistes de l'il-31
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
KR101367544B1
(ko)
*
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
WO2007008943A2
(fr)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Proteines optimisees qui ciblent la molecule ep-cam
|
PL1912675T3
(pl)
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
PT1915397E
(pt)
|
2005-08-19 |
2015-04-30 |
Univ Pennsylvania |
Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
|
CA2624189A1
(fr)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Variants de fc dotes de proprietes de liaison aux recepteurs fc optimisees
|
JP4860703B2
(ja)
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗cd30抗体
|
JP5052517B2
(ja)
|
2005-10-06 |
2012-10-17 |
イーライ リリー アンド カンパニー |
抗ミオスタチン抗体
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
CA2625773C
(fr)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition du recepteur de l'interleukin-6 (il-6) favorisant la transplantation d'ilots pancreatiques
|
AR058135A1
(es)
|
2005-10-21 |
2008-01-23 |
Chugai Pharmaceutical Co Ltd |
Agentes para el tratamiento de cardiopatias
|
US8679490B2
(en)
*
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AR057579A1
(es)
|
2005-11-23 |
2007-12-05 |
Merck & Co Inc |
Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
|
WO2007060411A1
(fr)
|
2005-11-24 |
2007-05-31 |
Ucb Pharma S.A. |
Anticorps anti-tnf alpha qui inhibent sélectivement le signal tnf alpha par le p55r
|
US20090269335A1
(en)
|
2005-11-25 |
2009-10-29 |
Keio University |
Therapeutic agent for prostate cancer
|
WO2007076200A2
(fr)
|
2005-11-28 |
2007-07-05 |
Medimmune, Inc. |
Antagonistes de hmgb1 et/ou rage et leurs procedes d'utilisation
|
CA2631184A1
(fr)
|
2005-11-28 |
2007-05-31 |
Genmab A/S |
Anticorps monovalents recombines et leurs procedes de production
|
EP2380588B1
(fr)
|
2005-12-12 |
2015-08-05 |
AC Immune S.A. |
Vaccin therapeutiqe
|
EP1977763A4
(fr)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Préparation stabilisatrice contenant des anticorps
|
HUE034269T2
(en)
|
2005-12-29 |
2018-02-28 |
Janssen Biotech Inc |
Human anti-IL-23 antibodies, preparations, methods and applications
|
US8771686B2
(en)
|
2006-01-27 |
2014-07-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
US20070190056A1
(en)
|
2006-02-07 |
2007-08-16 |
Ravi Kambadur |
Muscle regeneration compositions and uses therefor
|
JP4179517B2
(ja)
|
2006-02-21 |
2008-11-12 |
プロテノバ株式会社 |
イムノグロブリン親和性リガンド
|
WO2007097361A1
(fr)
|
2006-02-21 |
2007-08-30 |
Protenova Co., Ltd. |
Ligand presentant une affinite pour les immunoglobulines
|
SI1988882T1
(sl)
|
2006-03-02 |
2015-07-31 |
Alexion Pharmaceuticals, Inc. |
Podaljšanje preživetja alografta z inhibiranjem aktivnosti komplementa
|
EP1991275B1
(fr)
|
2006-03-08 |
2014-11-05 |
Archemix LLC |
Aptamères de liaison du complément et agents anti-c5 utiles dans le traitement de troubles oculaires
|
CA3022097C
(fr)
|
2006-03-15 |
2020-10-27 |
Alexion Pharmaceuticals, Inc. |
Traitement de patients souffrant d'hemoglobinurie paroxystique nocturne par un inhibiteur de complement
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
AU2007227963A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Kyowa Hakko Kirin Co., Ltd. |
Agonist antibody to human thrombopoietin receptor
|
WO2007126876A2
(fr)
|
2006-03-28 |
2007-11-08 |
Biogen Idec Ma Inc. |
Anticorps anti-igf-1r et utilisations de ceux-ci
|
WO2007114325A1
(fr)
*
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de modification d'anticorps pour purifier un anticorps bispécifique
|
EP4001409A1
(fr)
|
2006-03-31 |
2022-05-25 |
Chugai Seiyaku Kabushiki Kaisha |
Procédés pour le contrôle de la pharmacocinétique sanguine d'anticorps
|
EP3088410A3
(fr)
|
2006-04-05 |
2016-12-28 |
AbbVie Biotechnology Ltd |
Purification d'anticorps
|
US9260516B2
(en)
*
|
2006-04-07 |
2016-02-16 |
Osaka University |
Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007137984A2
(fr)
|
2006-05-25 |
2007-12-06 |
Glaxo Group Limited |
Immunoglobulines
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
CL2007001665A1
(es)
|
2006-06-08 |
2008-01-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
|
ES2415655T3
(es)
*
|
2006-06-15 |
2013-07-26 |
The Board Of Trustees Of The University Of Arkansas |
Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
ES2457072T3
(es)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
DE102006038844B4
(de)
|
2006-08-18 |
2018-03-22 |
Robert Bosch Gmbh |
Vorrichtung und Verfahren zur Ansteuerung von Personenschutzmittel
|
KR101123531B1
(ko)
|
2006-09-05 |
2012-04-20 |
일라이 릴리 앤드 캄파니 |
항-마이오스타틴 항체
|
DK2066349T3
(da)
|
2006-09-08 |
2012-07-09 |
Medimmune Llc |
Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme
|
CA2660795C
(fr)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Anticorps optimises ciblant l'antigene hm1.24
|
JP2008104147A
(ja)
|
2006-09-19 |
2008-05-01 |
Ricoh Co Ltd |
撮像装置、撮像システム、画像データ処理方法およびプログラム
|
CA3163418A1
(fr)
|
2006-10-06 |
2008-05-22 |
Jeffrey S. Isenberg |
Prevention de l'ischemie tissulaire et methodes et compositions associees
|
US20100034194A1
(en)
*
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
WO2008121160A2
(fr)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Anticorps optimisés qui ciblent cd5
|
CN100455598C
(zh)
|
2006-11-29 |
2009-01-28 |
中国抗体制药有限公司 |
功能人源化抗人cd20抗体及其应用
|
WO2008091798A2
(fr)
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Anticorps de ca9 optimises et methodes d'utilisation associees
|
JP5357778B2
(ja)
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化cd40抗体および前記を使用する方法
|
TWI438208B
(zh)
|
2007-01-23 |
2014-05-21 |
Chugai Pharmaceutical Co Ltd |
抑制慢性排斥反應之藥劑
|
WO2008090960A1
(fr)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
Composition d'anticorps génétiquement recombinés capable de se lier spécifiquement au ganglioside gm2
|
WO2008092117A2
(fr)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Nouvelles insertions, délétions et substitutions d'immunoglobulines
|
WO2008098115A2
(fr)
|
2007-02-07 |
2008-08-14 |
Xencor, Inc. |
Anti-corps igf-1r optimisés et procédés utilisant ceux-ci
|
EP2069404B1
(fr)
*
|
2007-02-14 |
2011-01-05 |
Vaccinex, Inc. |
Anticorps humanises anti-cd100
|
PL2426144T3
(pl)
|
2007-02-23 |
2019-05-31 |
Merck Sharp & Dohme |
Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
|
US7744874B2
(en)
|
2007-03-20 |
2010-06-29 |
Eli Lilly And Company |
Anti-sclerostin antibodies
|
EP2129681A2
(fr)
|
2007-03-22 |
2009-12-09 |
Novartis Ag |
Antigènes c5 et leurs utilisations
|
CL2008001071A1
(es)
|
2007-04-17 |
2009-05-22 |
Smithkline Beecham Corp |
Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
|
GB0708002D0
(en)
|
2007-04-25 |
2007-06-06 |
Univ Sheffield |
Antibodies
|
NZ581395A
(en)
|
2007-05-14 |
2012-08-31 |
Biogen Idec Inc |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
DK2176298T3
(en)
|
2007-05-30 |
2018-02-12 |
Xencor Inc |
Methods and compositions for inhibiting CD32B-expressing cells
|
EP2155790A1
(fr)
|
2007-05-31 |
2010-02-24 |
Genmab A/S |
Procédé d'extension de la demi-vie de molécules exogènes ou endogènes solubles
|
KR101530723B1
(ko)
|
2007-06-25 |
2015-06-22 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
|
CN106366192B
(zh)
|
2007-06-25 |
2020-03-27 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
CN101796408B
(zh)
|
2007-06-29 |
2014-05-07 |
奎斯特诊断投资公司 |
用液相层析-质谱法分析体液内的氨基酸
|
EP3246045A1
(fr)
|
2007-07-26 |
2017-11-22 |
Osaka University |
Agents thérapeutiques pour une maladie inflammatoire oculaire comprenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
|
WO2009026117A2
(fr)
|
2007-08-16 |
2009-02-26 |
Glaxo Group Limited |
Nouveaux composés
|
JP2010537985A
(ja)
|
2007-08-28 |
2010-12-09 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗igf−1r抗体およびその使用
|
CN101842116A
(zh)
|
2007-08-28 |
2010-09-22 |
比奥根艾迪克Ma公司 |
结合igf-1r多个表位的组合物
|
EP2031064A1
(fr)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Procédé d'augmentation de titres de protéines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
BRPI0817250A2
(pt)
|
2007-09-26 |
2014-06-17 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-receptor da il-6.
|
MX342551B
(es)
|
2007-09-26 |
2016-10-04 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
WO2009041734A1
(fr)
|
2007-09-26 |
2009-04-02 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps agoniste anti-récepteur de la thrombopoïétine humaine
|
WO2009041062A1
(fr)
|
2007-09-28 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps anti-glypican-3 dont la cinétique dans le plasma est améliorée
|
KR100888133B1
(ko)
|
2007-10-02 |
2009-03-13 |
에스케이에너지 주식회사 |
4종의 금속성분으로 구성된 다성분계 비스무스몰리브데이트 촉매 제조방법 및 상기촉매를 이용하여1,3-부타디엔을 제조하는 방법
|
AU2008308163B2
(en)
|
2007-10-02 |
2013-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
WO2009053358A1
(fr)
|
2007-10-22 |
2009-04-30 |
Merck Serono S.A. |
Procédé de purification de protéines de fusion avec fc
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
AR069333A1
(es)
|
2007-11-15 |
2010-01-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
|
US20110129459A1
(en)
*
|
2007-12-05 |
2011-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
CN104162155A
(zh)
|
2007-12-05 |
2014-11-26 |
中外制药株式会社 |
搔痒症治疗药
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP4098661A1
(fr)
|
2007-12-26 |
2022-12-07 |
Xencor, Inc. |
Variantes fc avec liaison altérée en fcrn
|
AU2008347438B2
(en)
|
2008-01-18 |
2013-08-29 |
Stichting Sanquin Bloedvoorziening |
Methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies
|
EP2238156B1
(fr)
|
2008-01-29 |
2014-10-01 |
Ablynx N.V. |
Procédés de stabilisation de protéines et de polypeptides
|
AU2015227424A1
(en)
|
2008-04-11 |
2015-10-01 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
NZ602884A
(en)
|
2008-04-11 |
2014-08-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
US9315577B2
(en)
*
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
CA2723987C
(fr)
|
2008-05-14 |
2019-06-11 |
Agriculture Victoria Services Pty Ltd |
Utilisation de l'angiogenine ou d'agonistes de l'angiogenine pour traiter des maladies et des troubles
|
CA2728243C
(fr)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Inhibiteur de neuro-invasion
|
MY159396A
(en)
|
2008-08-05 |
2016-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
EP2796469B1
(fr)
|
2008-09-17 |
2019-05-08 |
Xencor, Inc. |
Nouvelles compositions et méthodes de traitement de troubles induits par IgE
|
TWI440469B
(zh)
*
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
JP5229888B2
(ja)
|
2008-09-30 |
2013-07-03 |
独立行政法人産業技術総合研究所 |
弱酸性域での易解離性を向上したプロテインa変異型タンパク質及び抗体捕捉剤
|
CN110317272A
(zh)
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
HRP20230167T1
(hr)
|
2008-11-10 |
2023-03-31 |
Alexion Pharmaceuticals, Inc. |
Postupci i pripravci za liječenje poremećaja povezanih s komplementom
|
WO2010058860A1
(fr)
|
2008-11-18 |
2010-05-27 |
株式会社シノテスト |
Procédé de mesure et réactif de mesure pour la protéine c-réactive dans un échantillon
|
KR20110091780A
(ko)
|
2008-11-25 |
2011-08-12 |
앨더 바이오파마슈티컬즈, 인코포레이티드 |
악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il6의 길항제
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
EP2389192A4
(fr)
|
2009-01-23 |
2013-01-16 |
Biogen Idec Inc |
Polypeptides fc stabilisés avec une fonction effectrice réduite et procédés d'utilisation
|
EP2400981A4
(fr)
*
|
2009-02-26 |
2013-02-27 |
Lpath Inc |
Conception d'anticorps humanisé anti-facteur d'activation plaquettaire à l'aide de modèles d'anticorps anti-lipide
|
JP5787446B2
(ja)
*
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP5717624B2
(ja)
*
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
RU2565809C2
(ru)
|
2009-03-19 |
2015-10-20 |
Чугаи Сейяку Кабусики Кайся |
Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
|
EP2233500A1
(fr)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Variantes Fc optimisées
|
KR20120024763A
(ko)
|
2009-05-15 |
2012-03-14 |
추가이 세이야쿠 가부시키가이샤 |
항axl 항체
|
US20120303083A1
(en)
|
2009-05-26 |
2012-11-29 |
The Johns Hopkins University |
Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease
|
US8609097B2
(en)
|
2009-06-10 |
2013-12-17 |
Hoffmann-La Roche Inc. |
Use of an anti-Tau pS422 antibody for the treatment of brain diseases
|
MX2011013748A
(es)
|
2009-06-23 |
2012-04-20 |
Alexion Pharma Inc |
Anticuerpos biespecificos que se unen a proteinas de complemento.
|
US8945511B2
(en)
|
2009-06-25 |
2015-02-03 |
Paul Weinberger |
Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
|
CN102471378B
(zh)
|
2009-06-26 |
2014-04-02 |
瑞泽恩制药公司 |
容易地分离的具有天然免疫球蛋白形式的双特异性抗体
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
EP2481752B1
(fr)
*
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Régions constantes modifiées d'un anticorps
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
JP5734988B2
(ja)
|
2009-10-06 |
2015-06-17 |
メディミューン リミテド |
Rsv特異的結合分子
|
EP2486141B1
(fr)
|
2009-10-07 |
2018-01-10 |
MacroGenics, Inc. |
Polypeptides contenant une région fc qui présentent une fonction d'effecteur améliorée due à des modifications de l'étendue de la fucosylation, et leurs méthodes d'utilisation
|
CA2778673A1
(fr)
|
2009-10-27 |
2011-05-05 |
Karen Margrete Miller |
Modification fonctionnelle des anticorps anti-nav 1.7
|
CN101875696B
(zh)
|
2009-11-11 |
2012-02-08 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗体及其制备方法与应用
|
EP2327725A1
(fr)
|
2009-11-26 |
2011-06-01 |
InflaRx GmbH |
Groupes caractéristiques à liaison anti-C5a avec une activité à blocage élevé
|
AU329016S
(en)
|
2009-12-03 |
2009-12-22 |
Non Entity 49398 |
Induction system with integral air filter
|
PL2522724T3
(pl)
|
2009-12-25 |
2020-07-13 |
Chugai Seiyaku Kabushiki Kaisha |
Sposób modyfikowania polipetydów do oczyszczania multimerów polipeptydowych
|
WO2011094593A2
(fr)
|
2010-01-28 |
2011-08-04 |
Ab Biosciences, Inc. |
Nouveaux anticorps d'affinité moindre et procédés de fabrication associés
|
CA2789416A1
(fr)
|
2010-02-09 |
2011-08-18 |
Glaxosmithkline Llc |
Nouvelles utilisations
|
TW201127310A
(en)
*
|
2010-02-11 |
2011-08-16 |
jin-zhu Chen |
Step-less finetuning buckle
|
ES2826894T3
(es)
|
2010-02-19 |
2021-05-19 |
Xencor Inc |
Nuevas inmunoadhesinas CTLA4-IG
|
JP5852021B2
(ja)
|
2010-03-01 |
2016-02-03 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
ドゴー病を処置するための方法および組成物
|
WO2011108714A1
(fr)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
Variante de région constante d'anticorps
|
JP5932670B2
(ja)
*
|
2010-03-11 |
2016-06-08 |
ライナット ニューロサイエンス コーポレイション |
pH依存性の抗原結合を有する抗体
|
JP2011184418A
(ja)
|
2010-03-11 |
2011-09-22 |
Tokyo Institute Of Technology |
親和性可変抗体
|
TW201206466A
(en)
|
2010-03-11 |
2012-02-16 |
Rinat Neuroscience Corp |
Antibodies with pH dependent antigen binding
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
BR112012027917A2
(pt)
|
2010-04-30 |
2017-11-28 |
Alexion Pharma Inc |
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
EP3029066B1
(fr)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Anticorps à points isoélectriques modifiés
|
NZ608206A
(en)
|
2010-08-16 |
2015-02-27 |
Amgen Inc |
Antibodies that bind myostatin, compositions and methods
|
MX349622B
(es)
|
2010-09-08 |
2017-08-07 |
Halozyme Inc |
Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
|
EP2640745B1
(fr)
|
2010-09-10 |
2018-11-07 |
MedImmune Limited |
Anticorps bivalents et bispécifiques dirigés contre il-6 et il-23
|
CN104998254A
(zh)
|
2010-11-08 |
2015-10-28 |
基因技术公司 |
皮下施用的抗-il-6受体抗体
|
KR102385507B1
(ko)
|
2010-11-30 |
2022-04-12 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
WO2012088247A2
(fr)
|
2010-12-22 |
2012-06-28 |
Medimmune, Llc |
Fragments et anticorps anti-c5/c5a/c5adesr
|
US20140080153A1
(en)
|
2011-01-07 |
2014-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
WO2012132067A1
(fr)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
Rétention de molécules de liaison d'antigène dans le plasma sanguin et procédé pour modifier l'immunogénicité
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
US20140112926A1
(en)
|
2011-03-16 |
2014-04-24 |
Amgen Inc. |
Fc VARIANTS
|
EP3825325A3
(fr)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Rétention de molécules de liaison à l'antigène dans le plasma sanguin et procédé de modification du caractère immunogène
|
PL2699261T3
(pl)
|
2011-04-19 |
2018-12-31 |
Amgen Inc. |
Metoda leczenia osteoporozy
|
BR112013027829B1
(pt)
|
2011-04-29 |
2022-05-10 |
Apexigen, Inc |
Anticorpos anti-cd40 ou fragmentos de ligação aos antígenos destes, composição que compreende os ditos anticorpos e uso da dita composição para tratar ou melhorar os sintomas de câncer, doença autoimune ou doença inflamatória
|
MX347691B
(es)
|
2011-05-04 |
2017-05-09 |
Omeros Corp |
Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
|
EP2714733B1
(fr)
|
2011-05-21 |
2019-01-23 |
MacroGenics, Inc. |
Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
|
CA2834589A1
(fr)
|
2011-05-25 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Procede de preparation de polypeptides contenant fc a proprietes ameliorees
|
CA2839986A1
(fr)
|
2011-06-20 |
2012-12-27 |
St. Louis University |
Ciblage de la jonction neuromusculaire pour un traitement
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
CA3186007A1
(fr)
|
2011-09-30 |
2013-04-04 |
Chugai Seiyaku Kabushiki Kaisha |
Bibliotheque de molecules de liaison dependant de la concentration ionique
|
CA2850322C
(fr)
|
2011-09-30 |
2023-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Molecule de liaison d'un antigene induisant une reponse immunitaire pour cibler l'antigene
|
US20140335089A1
(en)
|
2011-09-30 |
2014-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
WO2013047748A1
(fr)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
US20150299313A1
(en)
|
2011-10-05 |
2015-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
|
KR20140100532A
(ko)
|
2011-11-30 |
2014-08-14 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약
|
SG10201805584YA
(en)
|
2012-02-24 |
2018-08-30 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
|
EA036225B1
(ru)
|
2012-03-14 |
2020-10-15 |
Ридженерон Фармасьютикалз, Инк. |
Мультиспецифические антигенсвязывающие молекулы и их применения
|
LT2825037T
(lt)
|
2012-03-16 |
2019-08-12 |
Regeneron Pharmaceuticals, Inc. |
Graužikai, ekspresuojantys ph jautrias imunoglobulino sekas
|
RS57118B1
(sr)
|
2012-03-16 |
2018-06-29 |
Regeneron Pharma |
Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
|
DK2831117T3
(en)
|
2012-03-29 |
2017-12-18 |
Novimmune Sa |
ANTI-TLR4 ANTIBODIES AND APPLICATIONS THEREOF
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
JP5988659B2
(ja)
|
2012-04-09 |
2016-09-07 |
シャープ株式会社 |
送風機
|
US9605058B2
(en)
|
2012-05-01 |
2017-03-28 |
Glaxosmithkline Llc |
Antibodies against the CXC-ELR family of chemokines
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
DK2857420T3
(da)
|
2012-05-30 |
2020-11-23 |
Chugai Pharmaceutical Co Ltd |
Målvævsspecifikt antigenbindende molekyle
|
JP6433889B2
(ja)
|
2012-06-15 |
2018-12-05 |
ファイザー・インク |
Gdf−8に対する改善された拮抗抗体およびその使用
|
AU2013285355A1
(en)
|
2012-07-06 |
2015-01-29 |
Genmab B.V. |
Dimeric protein with triple mutations
|
TWI596115B
(zh)
|
2012-08-13 |
2017-08-21 |
再生元醫藥公司 |
具有pH-依賴性結合特性之抗-PCSK9抗體
|
US9133269B2
(en)
|
2012-08-24 |
2015-09-15 |
Anaptysbio, Inc. |
Humanized antibodies directed against complement protein C5
|
RU2729831C2
(ru)
|
2012-08-24 |
2020-08-12 |
Чугаи Сейяку Кабусики Кайся |
ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスFcγRII特異的Fc抗体
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
RS62009B1
(sr)
|
2012-09-13 |
2021-07-30 |
Bristol Myers Squibb Co |
Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
|
TW201418707A
(zh)
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
AU2013341353B2
(en)
|
2012-11-06 |
2017-03-16 |
Children's Medical Center Corporation |
Compositions and methods for modulating cell signaling
|
AR094271A1
(es)
|
2012-12-21 |
2015-07-22 |
Aveo Pharmaceuticals Inc |
Anticuerpos anti-gdf15
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
RU2015130100A
(ru)
|
2013-01-24 |
2017-03-03 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
TNF-альфа антиген-связывающие белки
|
AU2014213147B2
(en)
|
2013-01-31 |
2019-01-17 |
lmmunAbs Inc. |
C5 antibody and method for preventing and treating complement-related diseases
|
US9481725B2
(en)
|
2013-03-14 |
2016-11-01 |
Alderbio Holdings, Llc |
Antibodies to HGF and compositions containing
|
US20160032014A1
(en)
|
2013-03-15 |
2016-02-04 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
CN105530949A
(zh)
|
2013-03-15 |
2016-04-27 |
安姆根有限公司 |
人类受试者中的肌抑素拮抗作用
|
US9321686B2
(en)
|
2013-03-15 |
2016-04-26 |
Forta Corporation |
Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
|
KR102561553B1
(ko)
|
2013-03-15 |
2023-07-31 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014145159A2
(fr)
|
2013-03-15 |
2014-09-18 |
Permeon Biologics, Inc. |
Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation
|
CA2897334A1
(fr)
|
2013-03-29 |
2014-10-02 |
Alexion Pharmaceuticals, Inc. |
Compositions et procedes pour augmenter la demi-vie serique d'un agent therapeutique ciblant c5 complementaire
|
EP3783017A1
(fr)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Variant de région fc
|
LT2981822T
(lt)
|
2013-05-06 |
2020-12-28 |
Scholar Rock, Inc. |
Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
|
CA2911600A1
(fr)
|
2013-05-17 |
2014-11-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Anticorps anti-cxcl1, cxcl7 et cxcl8 et leurs applications
|
RU2655439C2
(ru)
|
2013-05-31 |
2018-05-28 |
Займворкс Инк. |
Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
|
RS63152B1
(sr)
|
2013-07-25 |
2022-05-31 |
Cytomx Therapeutics Inc |
Multispecifična antitela, multispecifična antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu
|
MX2016001969A
(es)
|
2013-08-14 |
2016-06-02 |
Novartis Ag |
Metodos para tratar la miositis por cuerpos de inclusion esporadica.
|
US20160184391A1
(en)
|
2013-08-16 |
2016-06-30 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
JP6456831B2
(ja)
|
2013-09-04 |
2019-01-23 |
プロテノバ株式会社 |
イムノグロブリン結合ドメイン多量体
|
EP2853898B1
(fr)
|
2013-09-27 |
2017-01-04 |
Medizinische Hochschule Hannover |
Analyse de la myostatine dans le sérum
|
RU2016129517A
(ru)
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
EP3100056A2
(fr)
|
2014-01-27 |
2016-12-07 |
Novartis AG |
Biomarqueurs prédictifs de l'atrophie musculaire, procédé et utilisation associés
|
KR102472816B1
(ko)
|
2014-02-20 |
2022-11-30 |
알러간, 인코포레이티드 |
보체 성분 c5 항체
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
CN106459192B
(zh)
|
2014-06-30 |
2021-08-03 |
默克专利股份公司 |
具有pH依赖性抗原结合的抗TNFa抗体
|
WO2016073853A1
(fr)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
|
WO2016073879A2
(fr)
|
2014-11-06 |
2016-05-12 |
Scholar Rock, Inc. |
Anticorps liés à des facteurs de croissance transformants et utilisations de ceux-ci
|
CA2969800A1
(fr)
|
2014-12-08 |
2016-06-16 |
Novartis Ag |
Antagonistes de la myostatine ou de l'activine utilisables en vue du traitement de la sarcopenie
|
AU2015365167B2
(en)
|
2014-12-19 |
2021-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies and methods of use
|
SG11201700841QA
(en)
|
2014-12-19 |
2017-03-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
2種以上の抗c5抗体の組み合わせおよび使用方法
|
CN114773469A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
JP6130983B2
(ja)
|
2015-02-27 |
2017-05-17 |
中外製薬株式会社 |
Il−6関連疾患治療用組成物
|
US20190135903A1
(en)
|
2015-03-31 |
2019-05-09 |
Alexion Pharmaceuticals, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
|
MX2017013267A
(es)
|
2015-04-15 |
2018-08-15 |
Regeneron Pharma |
Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
|
EP3288586A1
(fr)
|
2015-05-01 |
2018-03-07 |
Alexion Pharmaceuticals, Inc. |
Efficacité d'un anticorps anti-c5 dans la prévention du rejet à médiation par les anticorps chez des receveurs sensibilisés d'une greffe de rein
|
US20180142010A1
(en)
|
2015-06-26 |
2018-05-24 |
Alexion Pharmaceuticals, Inc. |
Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
US10940126B2
(en)
|
2015-07-03 |
2021-03-09 |
Camilla Svensson |
Inhibition of IL-8 in the treatment of pain and/or bone loss
|
EP3922645A1
(fr)
|
2015-09-15 |
2021-12-15 |
Scholar Rock, Inc. |
Anticorps anti-pro/myostatine latente et leurs utilisations
|
CA2993423C
(fr)
|
2015-09-18 |
2024-03-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps de liaison a l'il-8 et leurs utilisations
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
KR102467124B1
(ko)
|
2015-12-18 |
2022-11-15 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 사용 방법
|
WO2017104783A1
(fr)
|
2015-12-18 |
2017-06-22 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
US10287345B2
(en)
|
2016-01-08 |
2019-05-14 |
Scholar Rock, Inc. |
Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
|
EP3402816A1
(fr)
|
2016-01-11 |
2018-11-21 |
Alexion Pharmaceuticals, Inc. |
Dosage et administration d'anticorps anti-c5 pour traitement
|
WO2017132259A1
(fr)
|
2016-01-25 |
2017-08-03 |
Shire Human Genetic Therapies, Inc. |
Anticorps anti-c5 à commutation ph améliorée
|
KR20230169484A
(ko)
|
2016-06-13 |
2023-12-15 |
스칼러 락, 인크. |
미오스타틴 억제제의 용도 및 조합 요법
|
CA3027487A1
(fr)
|
2016-06-14 |
2017-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anticorps anti-c5 et leurs utilisations
|
MY187848A
(en)
|
2016-06-17 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
MX2018014375A
(es)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y metodos de uso.
|
SG11201801024XA
(en)
|
2016-08-05 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Therapeutic or preventive compositions for il-8-related diseases
|
WO2018139623A1
(fr)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps anti-sclérostine et procédés d'utilisation
|
SG10201908697XA
(en)
|
2017-01-31 |
2019-10-30 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
KR20190128198A
(ko)
|
2017-03-14 |
2019-11-15 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
MA49886A
(fr)
|
2017-03-16 |
2020-06-24 |
Medimmune Ltd |
Anticorps anti-par2 et leurs utilisations
|
CA3058023A1
(fr)
|
2017-04-03 |
2018-10-11 |
Inflarx Gmbh |
Traitement de maladies inflammatoires par des inhibiteurs de l'activite de c5a
|
CN111868081A
(zh)
|
2017-10-26 |
2020-10-30 |
亚力兄制药公司 |
用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
|
BR112020010916A2
(pt)
|
2017-12-04 |
2020-11-17 |
Ra Pharmaceuticals, Inc |
moduladores da atividade do complemento
|
CN112512563A
(zh)
|
2018-08-01 |
2021-03-16 |
中外制药株式会社 |
用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
|
AU2020273072A1
(en)
|
2019-04-10 |
2021-12-09 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying Fc region-modified antibody
|